Study of Genetic Variation in TRAF3IP2 rs13190932 and Its Link to Psoriasis, Psoriatic Arthritis, and Response to Methotrexate Treatment

What this Trial Is About

Psoriasis and psoriatic arthritis PsA are chronic inflammatory diseases affecting skin and joints, with PsA occurring in up to 30% of psoriasis patients. This research aims to explore the genetic variation in the TRAF3IP2 gene and its association with psoriasis, PsA, and the treatment effects of methotrexate. The study focuses on understanding how this gene may influence disease characteristics and treatment outcomes. Participants include about 30 individuals with psoriasis, 10 with psoriatic arthritis, and 10 healthy controls. The study evaluates the response to methotrexate therapy, a common treatment for moderate to severe psoriasis, over a period of 3 months. Patients will be classified based on disease severity and genetic testing of the TRAF3IP2 gene will be performed to assess its role in treatment response. During the study, participants will undergo clinical assessments of their skin and joint symptoms, including PASI scoring for psoriasis severity. Follow-up visits will monitor treatment effects and safety. Researchers will analyze genetic data alongside clinical outcomes to evaluate methotrexates impact. The study is randomized without masking and includes a total participation age range of 18 to 70 years, with ongoing monitoring throughout the treatment period.

Genetic Variation in TRAF3IP2 (rs13190932)